Trioxifene (INN; developmental code LY-133,314), or as the salt trioxifene mesylate (USAN), is a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for the ERα and antagonistic activity against ERα-mediated gene expression, that was under preclinical and clinical development by Eli Lilly and Company for breast cancer and prostate cancer,[1] but was abandoned.

[2]: 11 [3][4] Its affinity for the rat estrogen receptor was reported to be 20% relative to estradiol.

[5][6]

This antineoplastic or immunomodulatory drug article is a stub.

You can help Wikipedia by expanding it.